Placeholder Banner

BIO Statement on Russia's Decision To Legalize Patent Theft

March 11, 2022
Media Contact
JG
2027471281

“Retaliation of this kind will only serve to isolate Russian science and technology from the international mainstream. At the end of the day those who will be most hurt by this decision will not be innovative global companies, but Russian patients, scientists and consumers.

“The reality is that global science and international cooperation will go on, just without Russia, further deepening their isolation and further darkening the long-term prospects for the Russian people, their economy and their society. This is just one more example of how myopic and dangerous decisions by Russian leadership are harming the Russian people.

“BIO and our members strongly support efforts to ensure patients have access to medicines, both existing and yet to be created. Strong intellectual property protections are vital to a vibrant market for innovative biotechnology and for developing new treatments for patients with unmet medical needs. We urge the US government and our allies to pursue all efforts to both ensure patients have access to necessary medicines and for companies to have certainty that intellectual property is protected and promoted.”

Discover More
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning…
Biotechnology companies are hard at work on the cutting-edge innovations we need, but those breakthroughs are at risk from current tax policy. The Biotechnology Innovation Organization, which represents more than 1,000 biotech companies, thanks…